Continue » Regeneron's purchase is still subject to court approval. If it gets a green light, as expected, the company could gain access to genetic data from more than 15 million 23andMe ...

Well, we could find out. Regeneron's purchase is still subject to court approval. If it gets a green light, as expected, the company could gain access to genetic data from more than 15 million ...

Regeneron Pharmaceuticals, Inc. REGN announced encouraging initial results from two cohorts of the early-stage study on oncology drug linvoseltamab. LINKER-MM2 is a phase Ib, open-label clinical ...

A biotech future built on data: Regeneron’s acquisition of 23andMe blurs the line between pharmaceutical innovation and genetic surveillance. Unsplash+ “We are pleased to have reached a ...

With support from Sanofi and Regeneron, Viz.ai will investigate the use of the Viz COPD module, a care acceleration solution that will leverage electronic health record (EHR) data and artificial ...

Regeneron Pharmaceuticals has agreed to acquire 23andMe’s consumer genetics business and assets for $256 million, following 23andMe’s Chapter 11 bankruptcy. GOP Calls for Investigation into ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...